Randomized, multicenter, phase ii study of co-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: Including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4453-4461

  Poplin, Elizabeth ^a   Wasan, Harpreet ^e   Rolfe, Lindsey ^b   Raponi, Mitch ^b   Ikdahl, Tone ^g   Bondarenko, Ihor ^h   Davidenko, Irina ^j   Bondar, Volodymyr ⁱ   Garin, August ^k   Boeck, Stefan ^l   Ormanns, Steffen ^l   Heinemann, Volker ^l   Bassi, Claudio ^m   Evans, T R Jeffrey ^f   Andersson, Roland ⁿ   Hahn, Hejin ^c   Picozzi, Vince ^c   Dicker, Adam ^d   Mann, Elaina ^b   Voong, Cynthia ^b   Kaur, Paramjit ^e   Isaacson, Jeff ^b   Allen, Andrew ^b   more..

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b Clovis Oncology Inc   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d RADIATION THERAPY ONCOLOGY GROUP   (United States)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Dnipropetrovsk State Medical Academy   (Ukraine)

ⁱ Donetsk Regional Antitumor Center   (Ukraine)

^j Clinical Oncology Center 1   (Russian Federation)

^k N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^l UNIVERSITY OF MUNICH   (Germany)

^m UNIVERSITY HOSPITAL OF VERONA   (Italy)

ⁿ LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CO 101; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE ELAIDATE; SLC29A1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TISSUE MICROARRAY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY; ADENOCARCINOMA; AGED; ANEMIA; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; IN VITRO STUDY; METABOLISM; METASTASIS; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; VERY ELDERLY; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; CHEMICALLY INDUCED; CLINICAL TRIAL; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; IN VITRO TECHNIQUES;

EID: 84894297251     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.0826     Document Type: Article

References (29)

1. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997 (Pubitemid 27251144)
2. Mackey JR, Mani RS, Selner M, et al: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349-4357, 1998 (Pubitemid 28450036)
3. Farrell JJ, Elsaleh H, Garcia M, et al: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187-195, 2009
4. Regine WF, Winter KA, Abrams RA, et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299:1019-1026, 2008 (Pubitemid 351347058)
5. Neoptolemos JP, Cox TF, Greenhalf W, et al: Nucleotide transporters and dCK1 as prognostic markers for patients with resected pancreatic ductal adenocarcinoma with or without adjuvant gemcitabine or 5FU hENT1 tested with samples from patients randomized in the ESPAC1/3 trials. Presented at the European Pancreatic Club, Prague, Czech Republic, June 20, 2012
6. Spratlin J, Sangha R, Glubrecht D, et al: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10:6956-6961, 2004 (Pubitemid 39383046)
7. Giovannetti E, Del Tacca M, Mey V, et al: Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66:3928-3935, 2006
8. Maréchal R, Mackey JR, Lai R, et al: Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15: 2913-2919, 2009
9. Marechal R, Bachet JB, Mackey JR, et al: Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143:664-674.e1-6, 2012
10. Morinaga S, Nakamura Y, Watanabe T, et al: Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol 19:S558-S564, 2012 (suppl 3)
11. Hagihara A, Hiraoka S, Ikeda M, et al: HENT1 expression might be a useful biomarker to predict prognosis in patients with resected pancreatic cancer. Pancreas 38:999, 2009 (abstr)
12. Kondo N, Murakami Y, Uemura K, et al: Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. Ann Surg Oncol 3:S646-S655, 2012 (suppl 3)
13. Fujita H, Ohuchida K, Mizumoto K, et al: Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12:807-817, 2010
14. Murata Y, Hamada T, Kishiwada M, et al: Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepatobiliary Pancreat Sci 19:413-425, 2012
15. Adema AD, Smid K, Losekoot N, et al: Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs 30:1908-1916, 2012
16. Bergman AM, Adema AD, Balzarini J, et al: Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs 29:456-466, 2011
17. Venugopal B: Gemcitabine elaidate. Drug Future 36:427-432, 2011
18. Altman DG, McShane LM, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. BMC Med 10:51, 2012
19. Nilsson B, Hendlisz A, Castella M, et al: First in-human study of a novel nucleoside analogue, intravenous CP-4126, in patients with advanced solid tumors. J Clin Oncol 27, 2009 (suppl 15S, abstr 2577)
20. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
21. Mackey JR, Jennings LL, Clarke ML, et al: Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 8:110-116, 2002 (Pubitemid 34101465)
22. McCarty S: Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46:4244s- 4248s, 1986 (suppl)
23. Philip PA, Mooney M, Jaffe D, et al: Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27:5660-5669, 2009
24. García-Manteiga J, Molina-Arcas M, Casado FJ, et al: Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2,2- difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9:5000-5008, 2003 (Pubitemid 37323307)
25. Neesse A, Michl P, Frese KK, et al: Stromal biology and therapy in pancreatic cancer. Gut 60: 861-868, 2011
26. Nakahira S, Nakamori S, Tsujie M, et al: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120:1355-1363, 2007
27. Itoi T, Sofuni A, Fukushima N, et al: Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol 42:389-394, 2007 (Pubitemid 47097256)
28. Akita H, Zheng Z, Takeda Y, et al: Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28:2903-2909, 2009
29. Mackey JR, Yao SY, Smith KM, et al: Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91:1876- 1881, 1999